Markowitz Joseph, MacKerell Alexander D, Weber David J
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Mini Rev Med Chem. 2007 Jun;7(6):609-16. doi: 10.2174/138955707780859422.
Typically, malignant melanoma has wild-type p53, and yet this cancer proliferates. S100B, which binds p53 and is up-regulated in melanoma, down-regulates wild-type p53 tumor suppressor function. Inhibitors of the S100B-p53 interaction were identified using computer aided drug design (CADD) combined with NMR methodologies and represent potentially new chemotherapeutics for melanoma.
通常情况下,恶性黑色素瘤具有野生型p53,但这种癌症仍会增殖。S100B可与p53结合且在黑色素瘤中上调,它会下调野生型p53肿瘤抑制功能。利用计算机辅助药物设计(CADD)结合核磁共振方法鉴定出了S100B与p53相互作用的抑制剂,这些抑制剂可能是黑色素瘤潜在的新型化疗药物。